Beam Therapeutics (BEAM)

Executive Summary

Beam Therapeutics (NASDAQ: BEAM) is a leading precision genetic medicine company leveraging its proprietary base editing platform to develop potentially curative therapies for serious diseases. Unlike traditional CRISPR-Cas9, base editing enables single-letter DNA changes without double-strand breaks, offering a more precise and potentially safer approach. Beam's pipeline includes seven disclosed programs targeting hematologic disorders, immunology-oncology, and rare diseases. The lead candidate, BEAM-101, is in Phase 1/2 for sickle cell disease and beta-thalassemia, with initial data expected in 2026. Other advanced programs include BEAM-201 (anti-CD7 CAR-T for T-cell acute lymphoblastic leukemia/lymphoma, Phase 1/2) and BEAM-302 (alpha-1 antitrypsin deficiency, Phase 1/2). Beam also has BEAM-301 for glycogen storage disease type Ia and BEAM-103 in a Phase 1 healthy volunteer study. The company benefits from a strong cash position and a seasoned management team, positioning it to advance its pipeline toward proof-of-concept readouts.

Upcoming Catalysts (preview)

• Q3 2026BEAM-101 Phase 1/2 Safety and Efficacy Data Update60% success
• Q2 2026BEAM-103 Phase 1 Healthy Volunteer Study Results80% success
• Q4 2026BEAM-201 Phase 1/2 Initial Efficacy Data in T-ALL/LBL55% success